Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 302

1.
2.

Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.

Bunn PA Jr, Thatcher N.

Oncologist. 2008;13 Suppl 1:37-46. doi: 10.1634/theoncologist.13-S1-37. Review.

3.

Second- and third-line treatments in non-small cell lung cancer.

Kumar A, Wakelee H.

Curr Treat Options Oncol. 2006 Jan;7(1):37-49. Review.

PMID:
16343367
4.

Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.

Patel JD, Pasche B, Argiris A.

Crit Rev Oncol Hematol. 2004 Jun;50(3):175-86. Review.

PMID:
15182824
6.

Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.

Bonomi PD, Buckingham L, Coon J.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4606-12. Review.

7.

Epidermal growth factor receptor-targeted agents for lung cancer.

Martin P, Kelly CM, Carney D.

Cancer Control. 2006 Apr;13(2):129-40. Review.

8.

[Second-line treatment and targeted therapy of advanced lung cancer].

Nakamura Y, Yamamoto N.

Gan To Kagaku Ryoho. 2009 May;36(5):710-6. Japanese.

PMID:
19461168
9.

Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer.

Itaya T, Yamaoto N, Ando M, Ebisawa M, Nakamura Y, Murakami H, Asai G, Endo M, Takahashi T.

Cancer Sci. 2007 Feb;98(2):226-30.

10.

Recent developments of targeted therapies in the treatment of non-small cell lung cancer.

Rossi A, Maione P, Colantuoni G, Ferrara C, Rossi E, Guerriero C, Nicolella D, Falanga M, Palazzolo G, Gridelli C.

Curr Drug Discov Technol. 2009 Jun;6(2):91-102. Review.

PMID:
19519336
11.

Current management of advanced non-small cell lung cancer: targeted therapy.

Isobe T, Herbst RS, Onn A.

Semin Oncol. 2005 Jun;32(3):315-28. Review.

PMID:
15988686
12.

New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.

Crawford J.

J Natl Compr Canc Netw. 2003 Jan;1 Suppl 1:S78-86. Review.

PMID:
19795580
13.

Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?

Gebbia V.

Expert Opin Pharmacother. 2008 Jun;9(8):1321-37. doi: 10.1517/14656566.9.8.1321 . Review.

PMID:
18473707
14.

[Stage IV NSCLC. Biological treatments of lung cancer in 2008... and in the near future].

Bergot E, Levallet G, Zalcman G.

Rev Mal Respir. 2008 Oct;25(8 Pt 2):3S119-26. French.

PMID:
18971836
15.

Targeted therapies in lung cancer.

Pirker R, Filipits M.

Curr Pharm Des. 2009;15(2):188-206.

PMID:
19149612
16.

The role of EGFR inhibition in the treatment of non-small cell lung cancer.

Ray M, Salgia R, Vokes EE.

Oncologist. 2009 Nov;14(11):1116-30. doi: 10.1634/theoncologist.2009-0054. Epub 2009 Nov 5. Review.

17.

Molecularly-targeted therapies for non-small cell lung cancer.

Ramalingam S, Belani CP.

Expert Opin Pharmacother. 2005 Dec;6(15):2667-79. Review.

PMID:
16316305
18.

Targeted therapies for non-small cell lung cancer.

Dempke WC, Suto T, Reck M.

Lung Cancer. 2010 Mar;67(3):257-74. doi: 10.1016/j.lungcan.2009.10.012. Epub 2009 Nov 14. Review.

PMID:
19914732
19.

Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.

Mukherji D, Spicer J.

Expert Opin Investig Drugs. 2009 Mar;18(3):293-301. doi: 10.1517/13543780902762843 . Review.

PMID:
19243280
20.

Supplemental Content

Support Center